Masimo Board of Directors Sets the Record Straight on False and Misleading Claims
Retrieved on:
Thursday, June 1, 2023
Professional Services, Medical Devices, Health, Health Technology, Finance, General Health, Stork, IPO, FOR, Marketing, Confidentiality, NTM, Acquisition, Investment, The Wall Street Journal, Risk, MASI, Court, Total shareholder return, Compensated emancipation, Letter, Catalog, Stock dilution, Policy, Immunity, Consultant, Name, TAM, TSR, Employment, Disclosure, President's Management Advisory Board, SET, History, Government, Somatosensory system, Midas, Traction, Lead, Suggestion, Masimo, COVID, Entrust, Committee, MightySat-1, EPS, Holding company, Typesetting, Security (finance), Management, Tobacco, Property management, Life insurance, Private investigator, Audit, Cryptocurrency, Real estate, Nicholas H. Politan, DEI Holdings
The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management (“Politan”).
Key Points:
- The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management (“Politan”).
- If shareholders approve the expansion of the Board, we will consider Ms. Brennan along with the other Board candidates and add the two best to Masimo’s Board.
- On the other hand, Mr. Koffey is totally unqualified for the board of any medical technology company, much less Masimo’s Board.
- Mr. Koffey has not demonstrated the trustworthy and principled behavior that Masimo shareholders should expect from their Board members.